💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, trading cheap versus its own history.
Alkem Laboratories is scored on the pharma / healthcare framework. It keeps a healthy 15.4% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.83×). Free cash flow is worth about 0.5% of its market value.
Over the last 3 years revenue compounded at 9%/yr and profit at 33%/yr. Book value itself has compounded 15%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 16.7%. In the latest quarter profit grew 107% versus the prior quarter.
At 28× earnings, the stock sits at the 13th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~14%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 28.56 | — | — |
| P/B | 4.56 | 4.11 | worse |
| EV/EBITDA | 18.11 | 19.15 | better |
| ROE | 16.66 | — | — |
| ROCE | 18.61 | 6.87 | better |
| ROA | 10.57 | — | — |
| Quick Ratio | 1.86 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 9% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (33% vs 9%) — margin expansion is at work.
Operating margin has expanded from 11% to 19% — the business is keeping more of each rupee earned.
ROE at 16% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 6pp across the window.
EPS has grown every year — each share earns more than the last, consistently. 33% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (7% spread) — a predictable, non-seasonal revenue stream.
Profit jumped 107% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (19% → 13%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 49.7% — dispersed ownership; institutional flows drive the stock. Promoters reduced 1.5pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.